SUTRO BIOPHARMA INC just moved. Here's exactly what to do next.
Who to reach, what to say, and why now — on SUTRO BIOPHARMA INC, plus every contract, funding round, and exec hire that follows. Verified, ICP-ranked contacts on demand (email + mobile).
Used by professionals at BlackRock, Oracle, Kleiner Perkins, HubSpot, and other leading firms — built on 10 years of proprietary signal data.
Sutro Biopharma Inc. and Boehringer Ingelheim BioXcellence™ Partnership: Scaling Up Cell-Free Technology for Commercial Production
Contract Type
partnership
San FranciscoBiotechnologyDescription
Sutro Biopharma Inc. and Boehringer Ingelheim BioXcellence announced the successful application of Sutro’s proprietary cell-free expression technology on a commercial scale to manufacture luveltamab tazevibulin, a Tubulin FRα-targeting antibody-drug conjugate (ADC) designed to treat ovarian cancer and other FRα expressing cancers. This marked an industry milestone in large-scale GMP production at Boehringer’s manufacturing facility in Vienna, Austria.